comparemela.com
Home
Live Updates
SEL-212 Shows Significant Response Rates, sUA Reductions in
SEL-212 Shows Significant Response Rates, sUA Reductions in
SEL-212 Shows Significant Response Rates, sUA Reductions in Patients with Gout
Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.
Related Keywords
California ,
United States ,
San Diego ,
Herbert Baraf ,
George Washington University ,
American College Of Rheumatology ,
Bone Research ,
National Institute Of Arthritis ,
National Institute ,
Skin Diseases ,
Gout Refractory ,
Conventional Treatment ,
Primary Outcomes ,
Two Randomized ,
Double Blind ,
Multicenter Phase ,
American College ,